Products from BPS Bioscience require a minimum order value above 400€
Applications: Predict the MOA of the CAR design Measurements of antibody (scFV-CAR) specificity Screen and validate BCMA-expressing caner target cells
Background: The development of CAR-T cells is a complex process that requires I) screening and sequencing of mAbs that are specific to the cancer antigens; II) synthesis of scFv cDNA and clone into Chimeric Antigen Receptor (CAR) cassette in Lentivector (e.g. anti-BCMA scFv in 3rd generation CAR cassette in lentivector); III) packaging and production of high titer lentivirus CAR encoding lentivirus; IV) isolation, activation and expansion of patient-derived T cells that exhibit a specific cellular phenotype (e.g. CD4+ or CD8+ or a mix); V) and transduction of activated T cells with CAR-encoding lentivirus; VI) Validation of engineered CAR-T cells through FACS and functional analysis. BPS has developed an anti-BCMA CAR Jurkat/NFAT-luciferase stable reporter cell line, it is one of a series of reporter bioassays using CAR-T Lentivirus and Jurkat/NFAT-luciferase reporter cell lines. The anti-BCMA CAR Jurkat/NFAT-luciferase reporter cell line is a great system to predict the mechanism of action (MOA) and therapeutic potential of the anti-BCMA CAR lentivirus before using it with patient-derived primary T cells. It is a single cell clonal stable cell line developed by transducing the Jurkat/NFAT-Luciferase reporter cells with the anti-BCMA scFV CAR lentivirus (BPS Bioscience #79701).
Description: The anti-BCMA CAR Jurkat/NFAT-luciferase reporter cell line is a stable cell line made from the anti-BCMA scFV CAR lentivirus (BPS Bioscience #79701). It has been validated for anti BCMA-CAR expression by FACS, and for functional activation stimulated by both soluble BCMA protein (BPS Bioscience #79467) and BCMA/CHO target cells (BPS Bioscience #79500).
Host Cell Line: Jurkat
Mycoplasma Testing: The cell line has been screened using the PCR-based Venor™GeM Mycoplasma Detection kit (Sigma-Aldrich, #MP0025) to confirm the absence of Mycoplasma species.
Storage Stability: Immediately upon receipt, store in liquid nitrogen.
Supplied As: Each vial contains 2 x 10^6 cells in 1 ml of 10% DMSO and 90% FBS
Biosafety Level: BSL-1
References: 1. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. Wang et. al. J Hematol Oncol. 2019 Jun 11;12(1):59
2. Chimeric antigen receptor T cell therapy for multiple myeloma. Hasegawa et.al. Inflamm Regen. 2019 Jun 4;39:10.
3. Novel targets for the treatment of relapsing multiple myeloma. Giuliani et. al. Expert Rev Hematol. 2019 Jun 3:1-16.
4. Anti-BCMA antibodies in the future management of multiple myeloma. Gavriatopoulou et. al. Expert Rev Anticancer Ther. 2019 Apr;19(4):319-326.
English
Deutsch
